Andres M Kanner1, Eric Ashman2, David Gloss3, Cynthia Harden4, Blaise Bourgeois5, Jocelyn F Bautista6, Bassel Abou-Khalil7, Evren Burakgazi-Dalkilic8, Esmeralda Llanas Park9, John Stern10, Deborah Hirtz11, Mark Nespeca12, Barry Gidal13, Edward Faught14, Jacqueline French15. 1. 1University of Miami, Miller School of Medicine, FL. 2. 2Bronson Methodist Hospital, Kalamazoo, MI. 3. 3Charleston Area Medical Center, Charleston, WV. 4. 4Mount Sinai Beth Israel, New York, NY. 5. 5Children's Hospital, Harvard Medical School, Boston, MA. 6. 6Cleveland Clinic Foundation, Cleveland, OH. 7. 7Department of Neurology, School of Medicine, Nashville, TN. 8. 8Rowan University, Cooper Medical School, Cherry Hill, NJ. 9. 9Alexian Brothers Medical Group, Hoffman Estates, IL. 10. 10University of California in Los Angeles, School of Medicine, Los Angeles, CA. 11. 11University of Vermont Medical Center, Burlington, VT. 12. 12Children's Hospital, University of California San Diego School of Medicine, CA. 13. 13University of Wisconsin, School of Pharmacy, Madison, WI. 14. 14Emory University School of Medicine, Atlanta, GA. 15. 15New York University, New York City, NY.
Abstract
Objective: To update the 2004 American Academy of Neurology (AAN) guideline for managing treatment-resistant (TR) epilepsy with second- and third-generation antiepileptic drugs (AEDs). Methods: 2004 criteria were used to systematically review literature (January 2003 to November 2015), classify pertinent studies according to the therapeutic rating scheme, and link recommendations to evidence strength. Results: Forty-two articles were included. Recommendations: The following are established as effective to reduce seizure frequency (Level A): immediate-release pregabalin and perampanel for TR adult focal epilepsy (TRAFE); vigabatrin for TRAFE (not first-line treatment; rufinamide for Lennox-Gastuat syndrome (LGS) (add-on therapy). The following should be considered to decrease seizure frequency (Level B): lacosamide, eslicarbazepine, and extended-release topiramate for TRAFE (ezogabine production discontinued); immediate- and extended-release lamotrigine for generalized epilepsy with TR generalized tonic-clonic (GTC) seizures in adults; levetiracetam (add-on therapy) for TR childhood focal epilepsy (TRCFE) (1 month to 16 years), TR GTC seizures, and TR juvenile myoclonic epilepsy; clobazam for LGS (add-on therapy); zonisamide for TRCFE (6-17 years); oxcarbazepine for TRCFE (1 month to 4 years). The text presents Level C recommendations. AED selection depends on seizure/syndrome type, patient age, concomitant medications, and AED tolerability, safety, and efficacy. This evidence-based assessment informs AED prescription guidelines for TR epilepsy and indicates seizure types and syndromes needing more evidence. A recent FDA strategy allows extrapolation of efficacy across populations; therefore, for focal epilepsy, eslicarbazepine and lacosamide (oral only for pediatric use) as add-on or monotherapy in persons ≥4 years of age and perampanel as monotherapy received FDA approval.
Objective: To update the 2004 American Academy of Neurology (AAN) guideline for managing treatment-resistant (TR) epilepsy with second- and third-generation antiepileptic drugs (AEDs). Methods: 2004 criteria were used to systematically review literature (January 2003 to November 2015), classify pertinent studies according to the therapeutic rating scheme, and link recommendations to evidence strength. Results: Forty-two articles were included. Recommendations: The following are established as effective to reduce seizure frequency (Level A): immediate-release pregabalin and perampanel for TR adult focal epilepsy (TRAFE); vigabatrin for TRAFE (not first-line treatment; rufinamide for Lennox-Gastuat syndrome (LGS) (add-on therapy). The following should be considered to decrease seizure frequency (Level B): lacosamide, eslicarbazepine, and extended-release topiramate for TRAFE (ezogabine production discontinued); immediate- and extended-release lamotrigine for generalized epilepsy with TR generalized tonic-clonic (GTC) seizures in adults; levetiracetam (add-on therapy) for TR childhood focal epilepsy (TRCFE) (1 month to 16 years), TR GTC seizures, and TR juvenile myoclonic epilepsy; clobazam for LGS (add-on therapy); zonisamide for TRCFE (6-17 years); oxcarbazepine for TRCFE (1 month to 4 years). The text presents Level C recommendations. AED selection depends on seizure/syndrome type, patient age, concomitant medications, and AED tolerability, safety, and efficacy. This evidence-based assessment informs AED prescription guidelines for TR epilepsy and indicates seizure types and syndromes needing more evidence. A recent FDA strategy allows extrapolation of efficacy across populations; therefore, for focal epilepsy, eslicarbazepine and lacosamide (oral only for pediatric use) as add-on or monotherapy in persons ≥4 years of age and perampanel as monotherapy received FDA approval.
Authors: Jacqueline French; Christian Brandt; Daniel Friedman; Victor Biton; Lloyd Knapp; Verne Pitman; Marci Chew; Sarah Dubrava; Holly B Posner Journal: Epilepsia Date: 2014-06-24 Impact factor: 5.864
Authors: Martin J Brodie; William E Rosenfeld; Blanca Vazquez; Rajesh Sachdeo; Carlos Perdomo; Allison Mann; Santiago Arroyo Journal: Epilepsia Date: 2009-06-01 Impact factor: 5.864
Authors: Lindsay F Smegal; Alison J Sebold; Adrienne M Hammill; Csaba Juhász; Warren D Lo; Daniel K Miles; Angus A Wilfong; Alex V Levin; Brian Fisher; Karen L Ball; Anna L Pinto; Anne M Comi Journal: Pediatr Neurol Date: 2021-03-05 Impact factor: 4.210